Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis

Qingdu Liu,1 Olena Davidoff,1 Knut Niss,2 and Volker H. Haase1

1Departments of Medicine, Cancer Biology, and Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
2R&D Stem Cell Initiative, EMD Millipore Corp., Bedford, Massachusetts, USA.

Iron demand in bone marrow increases when erythropoiesis is stimulated by hypoxia via increased erythropoietin (EPO) synthesis in kidney and liver. Hepcidin, a small polypeptide produced by hepatocytes, plays a central role in regulating iron uptake by promoting internalization and degradation of ferroportin, the only known cellular iron exporter. Hypoxia suppresses hepcidin, thereby enhancing intestinal iron uptake and release from internal stores. While HIF, a central mediator of cellular adaptation to hypoxia, directly regulates renal and hepatic EPO synthesis under hypoxia, the molecular basis of hypoxia/HIF-mediated hepcidin suppression in the liver remains unclear. Here, we used a genetic approach to disengage HIF activation from EPO synthesis and found that HIF-mediated suppression of the hepcidin gene (Hamp1) required EPO induction. EPO induction was associated with increased erythropoietic activity and elevated serum levels of growth differentiation factor 15. When erythropoiesis was inhibited pharmacologically, Hamp1 was no longer suppressed despite profound elevations in serum EPO, indicating that EPO by itself is not directly involved in Hamp1 regulation. Taken together, we provide in vivo evidence that Hamp1 suppression by the HIF pathway occurs indirectly through stimulation of EPO-induced erythropoiesis.

Introduction

The increased production of erythrocytes and thus increased O2-carrying capacity of blood represents a major adaptation to systemic hypoxia. This important physiologic response consists of cell type–specific changes that include increased erythropoietin (EPO) production in kidney and liver and enhanced iron uptake and utilization as well as adjustments in the BM microenvironment that facilitate erythropoiesis. Erythropoiesis is stimulated by hypoxia via increased erythropoietin (EPO) synthesis in kidney and liver. Hepcidin, a small polypeptide produced by hepatocytes, plays a central role in regulating iron uptake by promoting internalization and degradation of ferroportin, the only known cellular iron exporter. Hypoxia suppresses hepcidin, thereby enhancing intestinal iron uptake and release from internal stores. While HIF, a central mediator of cellular adaptation to hypoxia, directly regulates renal and hepatic EPO synthesis under hypoxia, the molecular basis of hypoxia/HIF-mediated hepcidin suppression in the liver remains unclear. Here, we used a genetic approach to disengage HIF activation from EPO synthesis and found that HIF-mediated suppression of the hepcidin gene (Hamp1) required EPO induction. EPO induction was associated with increased erythropoietic activity and elevated serum levels of growth differentiation factor 15. When erythropoiesis was inhibited pharmacologically, Hamp1 was no longer suppressed despite profound elevations in serum EPO, indicating that EPO by itself is not directly involved in Hamp1 regulation. Taken together, we provide in vivo evidence that Hamp1 suppression by the HIF pathway occurs indirectly through stimulation of EPO-induced erythropoiesis.

Iron demand in bone marrow increases when erythropoiesis is stimulated by hypoxia via increased erythropoietin (EPO) synthesis in kidney and liver. Hepcidin, a small polypeptide produced by hepatocytes, plays a central role in regulating iron uptake by promoting internalization and degradation of ferroportin, the only known cellular iron exporter. Hypoxia suppresses hepcidin, thereby enhancing intestinal iron uptake and release from internal stores. While HIF, a central mediator of cellular adaptation to hypoxia, directly regulates renal and hepatic EPO synthesis under hypoxia, the molecular basis of hypoxia/HIF-mediated hepcidin suppression in the liver remains unclear. Here, we used a genetic approach to disengage HIF activation from EPO synthesis and found that HIF-mediated suppression of the hepcidin gene (Hamp1) required EPO induction. EPO induction was associated with increased erythropoietic activity and elevated serum levels of growth differentiation factor 15. When erythropoiesis was inhibited pharmacologically, Hamp1 was no longer suppressed despite profound elevations in serum EPO, indicating that EPO by itself is not directly involved in Hamp1 regulation. Taken together, we provide in vivo evidence that Hamp1 suppression by the HIF pathway occurs indirectly through stimulation of EPO-induced erythropoiesis.

Conflict of interest: Volker H. Haase serves on the Scientific Advisory Board of Akebia Therapeutics. Knut Niss was an employee of Pfizer Inc. and is now an employee of EMD Millipore Corp.

Citation for this article: J Clin Invest. 2012;122(12):4635–4644. doi:10.1172/JCI63924.
A direct effect of EPO on HAMP transcription has also been pos-
tulated. Studies with primary hepatocytes and HepG2 cells have
shown that EPO, in a dose-dependent fashion, is capable of regu-
larizing HAMP transcription via EPO receptor (EPOR) and CCAAT/
enhancer-binding protein (C/EBP) α activation (21). A fourth
model proposes that stimulation of erythropoiesis generates a
BM-derived signal that suppresses Hamp1 in the liver (22). Growth
differentiation factor 15 (GDF15), an iron- and O2- regulated (HIF-
indeendent) member of the TGF-β superfamily, is secreted from
maturing erythroblasts and suppresses HAMP transcription in
primary human hepatocytes and hepatoma cells (23, 24). Since
very high levels of serum GDF15 were found in patients with α- and β-thalassemia, it was proposed that GDF15 is the BM-derived
factor that suppresses hepcidin under conditions of stimulated
eythropoiesis (24). While high serum GDF15 levels were found in
patients with syndromes of ineffective erythropoiesis (24–27), the
association between serum GDF15 and serum hepcidin levels in
other forms of anemia was less evident. This raised the possibility
that GDF15 may be a marker of ineffective or apoptotic eryth-
poiesis. Nevertheless, its role in hepcidin regulation under physi-
ologic or other pathologic conditions remains to be elucidated (for
a recent review on this topic, see ref. 28).

To specifically dissect the role of the VHL/HIF/PHD axis and
EPO in the hypoxic suppression of hepcidin in vivo, we have used
a genetic approach to disengage Hif activation from Epo synthesis in
mice. We utilized tamoxifen-inducible Cre/loxP-mediated recombi-
nation to activate Hif-1 and Hif-2 via ablation of Vhl while simul-
taneously inactivating Epo. We found that hypoxia/Hif-mediated
suppression of Hamp1 required Epo inducibility and was associ-
ated with elevated serum Gdf15 levels. Including additional genetic
models, we furthermore demonstrate that increased erythropoietic
drive is required for Hamp1 suppression under conditions of hepatic
Hif activation irrespective of serum Epo levels. Our genetic data
establish that Hif activation in hepatocytes suppresses Hamp1 indi-
crectly through Epo-mediated stimulation of erythropoiesis.

Results

Conditional inactivation of Vhl results in Hif-dependent hepcidin sup-
pression. For the genetic dissection of hepcidin regulation by the
HIF oxygen-sensing pathway, we established a model of acute
Vhl inactivation using a globally expressed tamoxifen-inducible
Cre-recombinase under the control of the ubiquitin c promoter,
Ubc-cre/ERT2 (29). Although hepatocyte-specific Vhl inactivation
via Cre-recombinase driven by the albumin promoter suppresses
hepatic Hamp1 (8, 30), constitutive Hif activation in the liver has
profound effects on glucose and fatty acid metabolism and results
in sick animals that die from liver failure between the ages of 6
and 12 weeks (31), which makes the interpretation of hematologic
data difficult and limits experimental options. To achieve effi-
cient recombination in Ubc-cre/ERT2 mice that were homozygous
for the Vhl floxed allele, 4 doses of tamoxifen were administered
over a period of 7 days, followed by phenotypic analysis on day 8
(experimental time line is shown in Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JC163924DS1). Tamoxifen administration resulted in an approxi-
mately 75% reduction in hepatic Vhl mRNA levels, stabilization
of both Hif-1α and Hif-2α homologs, and increased expression of
Hif target genes, such as Epo, Vegf, and divalent metal transporter 1
(Dmt1) (Figure 1A and Supplemen tal Figure 1). Recombination
analysis by genomic PCR indicated efficient recombination in the
kidney and in other organs (Supplemental Figure 1 and data not
shown). Since hepatic and renal Epo synthesis were stimu-
lated in Vhl−/− mutant mice, serum Epo levels were elevated to 11733 ±
2170 pg/ml compared with Cre− control mice (235.3 ± 89.8 pg/ml).
This resulted in increased formation of CD71+Ter119+-positive
eythroblasts in spleen and BM (in spleen 59.33% ± 2.93% for
mutants vs. 18.2% ± 3.54% for control mice, and 32.2% ± 0.723% vs.
17.33% ± 3.48% in BM; n = 3 each), splenomegal y, and reticulo-
cytosis (12.64% ± 1.57% for mutants vs. 5.37% ± 0.35% for controls,
n = 6 each), all of which are consistent with increased erythropoi-
etic activity (Figure 1B and Supplemental Figure 1). Hematocrit
(Hct), hemoglobin (Hb), and rbc values in Vhl−/− mutants were not
different from controls at day 8 after the first tamoxifen injection
and were found to be increased at day 16; Hb values increased from
14.13 ± 0.186 g/dl in controls to 16.07 ± 0.73 g/dl in mutants on
day 16, n = 3 each (Supplemental Figure 1 and data not shown).
Hamp1 mRNA levels were undetectable in Vhl−/− livers by real-time
PCR analysis (Figure 1C). While serum iron levels did not differ
between mutants and Cre− controls, iron was decreased in Vhl−/−
livers, which was associated with reduced ferritin heavy chain-1
(H-ferritin) levels (Figure 1C). This is expected, as the ferritin 5′
UTR contains an iron response element (IRE) that mediates trans-
lational inhibition in the presence of low intracellular iron. Taken

Together, these results demonstrate that acute global inactivation
of Vhl results in increased erythropoietic activity and associates
with decreased Hamp1 expression in the liver.

To investigate the role of Hif in VHL-associated hepcidin
regulation, we generated mice that permitted global inactiva-
tion of both Hif-1α and Hif-2α in a Vhl−/−deficient background.
Epo and Vegf were not significantly induced or decreased in Vhl/
Hif-1/Hif-2−/−livers compared with Cre− littermate control mice
(Figure 2A), which suggests (a) that their increased expression
in Vhl−/− livers is Hif dependent and (b) that Hif-1 and Hif-2 do
not participate in their transcriptional regulation under base-
line, i.e., normoxic conditions. This is consistent with our previ-
ous studies in hepatocyte-specific Vhl-knockout mice, where we
identified Hif-2 as the main regulator of hepatic Epo synthesis.

With these studies, we demonstrated that inactivation of both
Hif-1α and Hif-2α in a Vhl−/− background completely abrogated
Epo induction (32). Consequently, serum Epo concentrations in
Vhl/Hif-1/Hif-2−/− mice did not significantly differ from those in
Cre− control mice (277.5 ± 61.66 pg/ml in mutants vs. 235.1 ±
50.69 pg/ml in controls; n = 3 and n = 5, respectively) (Figure 2B).
The abrogation of Epo induction in triple mutants was associated
with a statistically significant increase in Hamp1 mRNA levels in
Vhl/Hif-1/Hif-2−/− livers compared with Cre− controls, P = 0.0035
for n = 3. In summary, our data establish that the suppression of
Hamp1 in Vhl-defective livers requires Hif stabilization.

Hif-1 does not suppress hepcidin in Phd−/− livers. Since hepatic Hif-1
has been shown to participate in the regulation of Hamp1 in iron-defi-
ciency anemia (8), we made use of a mouse model that specifically
activates hepatic Hif-1 in a genetic background that is WT for Vhl.
We generated mice with hepatocyte-specific inactivation of Phd2.
Phd2, also known as EglN1, is the major Hif prolyl-4-hydroxylase
that targets Hif-α subunits for hydroxylation and subsequent protea-
somal degradation under normoxia. Phd2 inactivation in hepatocytes
(EglN1floxed/coloxAlbunum-cre) resulted in stabilization of Hif-1α, but not
of Hif-2α (Figure 3A), which is consistent with previous reports (33).
Surprisingly, Hamp1 expression levels in Phd2-deficient livers did not
change compared with controls (Figure 3B). Also, hepatocyte-specific
Phd2 inactivation did not increase Epo mRNA levels, nor did it stimulate erythropoietic BM activity, as an increase in blood reticulocytes and Hct was not observed (reticulocyte count: 5.93% ± 0.22% vs. 5.58% ± 0.381%; Hct: 54.33% ± 0.33% and 57.33% ± 0.33%, respectively, n = 3 each) (Figure 3, B and C). This is consistent with our previous observation that hepatic Epo synthesis is predominantly Hif-2 regulated (32). Our findings indicate that Hif-1α stabilization alone is not sufficient to suppress Hamp1 in hepatocytes. Furthermore, analysis of Phd2-knockout mice suggests that Hif-associated Hamp1 suppression is linked to Hif-2–dependent stimulation of erythropoiesis. Hif-mediated hepcidin suppression requires Epo inducibility. Our findings in liver-specific Phd2-knockout mice suggested that hepatic Hif-2 activation and/or Hif-2–stimulated erythropoiesis led to the suppression of Hamp1 in Vhl–/– livers. To determine whether Hif-induced Hamp1 suppression in Vhl–/– mice is dependent on the ability to synthesize Epo, we generated a genetic mouse model in which Hif activation can be dissociated from Epo synthesis and Epo-induced erythropoietic activity. In this model, both Hif-1 and Hif-2 are activated in hepatocytes and other cell types without any concomitant increase in renal and hepatic Epo production. For this purpose, we bred the Epo–2lox allele into the Vhl–2lox background and generated mice that permitted global, tamoxifen-inducible, and concurrent Vhl and Epo gene inactivation (Vhl2lox/2lox;Epo2lox/2lox;Ubc-cre/ERT2). While Vhl ablation in Vhl/Epo–/– mice resulted in stabilization of hepatic and renal Hif-1α and Hif-2α (Figure 4A) as well as increased Vegf and Dmt-1 mRNA levels (Supplemental Figure 2C), Epo mRNA was not induced in the liver and kidney (Figure 4B, hepatic and renal Epo mRNA levels in Vhl–/– mice are shown for comparative purposes). Serum Epo levels in Vhl/Epo–/– mice were slightly decreased (200.1 ± 46.6 pg/ml vs. 217.3 ± 33.4 pg/ml in control animals, n = 6 and 10, respectively), but not significantly different from control mice, while rbc numbers and Hct and Hb values were decreased compared with controls (Figure 4C and Supplemental Figure 2A). The rbc numbers and Hct

---

**Figure 1**

Inactivation of Vhl suppresses Hamp1. (A) Shown are real-time PCR analysis of Vhl and Vegf mRNA levels in Vhl–/– livers (n = 3) and Epo mRNA levels in Vhl–/– kidneys and livers (n = 3); analysis was performed on day 8 after the first tamoxifen injection. Relative mRNA expression levels were normalized to 18S ribosomal RNA. (B) Global inactivation of Vhl induces erythropoiesis. Shown are individual Hct values (n = 14 and 13, respectively), reticulocyte counts (%) (n = 6 each), and serum Epo concentrations (sEpo) (n = 3 each) from control and mutant mice and a representative picture of a control and a Vhl–/– spleen. Lower right panel shows a representative FACS plot of CD71/Ter119 double-stained BM and spleen cells from an individual control mouse and Vhl mutant. Percentages of CD71hi/Ter119hi–positive cells (right upper quadrant) are indicated. (C) Shown are relative expression levels of Hamp1 mRNA in control and Vhl–/– livers (n = 5 and 3, respectively) and serum iron and liver iron concentrations (n = 7 and 4, respectively). H-ferritin protein levels in control and Vhl–/– livers were determined by immunoblot in 3 mice, β-actin served as loading control. Asterisks indicate a statistically significant difference when comparisons were made to the control group: *P < 0.05; **P < 0.01; ***P < 0.001. Shown are arithmetic mean values ± SEM. Co, Cre-negative littermate control; retic, reticulocytes.
and Hb values decreased further over time; at day 16 after the first tamoxifen injection, mean Hct in Vhl/Epo–/– mutants was 24.03 ± 1.937%, mean Hb was 6.5 ± 0.59 g/dl, and mean rbc count was 5.01 ± 0.41 M/μl (n = 3), which is consistent with hypoproliferative anemia that develops in mice with global Epo inactivation (34).

Despite Hif-1α and Hif-2α stabilization in the liver, Hamp1 was no longer suppressed and increased significantly, by approximately 3-fold, P = 0.0032, n = 6 (Figure 4A). These findings indicate that (a) Hamp1 is not directly regulated by either Hif-1 or Hif-2 and (b) that its suppression is dependent on the induction of Epo synthesis, while acute Epo deficiency increases its transcription.

Since we established Epo dependence of VHL-associated Hamp1 regulation, we asked whether administration of recombinant EPO was able to overcome the genetic Epo deficiency and could restore Hamp1 suppression in Vhl/Epo–/– livers. For this, we administered 200 IU of recombinant human EPO (rhEPO) to Vhl/Epo–/– mice i.p. every day for 3 days prior to mouse phenotyping. While a rise in rbc numbers was not seen 4 days after the initiation of rhEPO treatment (Figure 4C), reticulocyte counts increased from 4.91% ± 0.61% to 10.44% ± 0.53% (n = 10 and 5, respectively), and CD71hiTer119hi-positive erythroblasts increased from 16.42% ± 5.28% to 45% ± 3.35% in spleen and from 16.5% ± 1.25% to 43.36% ± 2.78% in BM (n = 10 and 5, respectively).

**Figure 2**
Hamp1 suppression in Vhl+/– livers is Hif dependent. (A) Real-time PCR analysis of Vhl, Vegf, Epo, Hamp1, Dmt1, and Trf c expression in Vhl/Hif1a/Hif2a–/– livers. Relative mRNA expression levels were normalized to 18S ribosomal RNA. Bars represent arithmetic mean values ± SEM (n = 3). (B) Serum Epo concentrations and serum iron levels in Vhl/Hif1a/Hif2a–/– mice (n = 3). Circles and squares represent data points for individual mice. Error bars represent SEM. *P < 0.05; **P < 0.01, for comparisons with controls.

**Figure 3**
Hepatocyte-specific inactivation of Phd2 does not suppress Hamp1. (A) Hif-1α and Hif-2α protein levels in Phd2–/– livers. Ponceau staining is used to assess for equal protein loading. +Co, positive control sample obtained from Vhl–/– livers. (B) Hepatocyte-specific inactivation of Phd2 does not increase Epo mRNA and does not suppress Hamp1 mRNA levels in Phd2–/– livers. Shown are relative mRNA expression levels normalized to 18S ribosomal RNA in mutant and control livers. Corresponding renal Epo mRNA levels are shown for comparison (n = 3). (C) Hct, reticulocyte counts, and serum Epo and serum iron levels in control and Phd2 mutant mice (n = 3 each). Shown are mean values ± SEM. For statistical analysis, mutants were compared with controls.
respectively) (Figure 4C and Supplemental Figure 2). Restoration of erythropoietic activity suppressed Hamp1 in Vhl/Epo–/– livers (Figure 4A). Taken together, our data provide genetic evidence that Hamp1 suppression in Vhl–/– livers requires intact Epo synthesis and is not directly dependent on Hif-1α and/or Hif-2α activation in hepatocytes.

Hif-mediated hepcidin suppression requires erythropoietic activity and associates with increased serum Gdf15 levels. Although our genetic data established a clear role for Epo in the regulation of Hamp1, it was unclear whether Epo effects on Vhl–/– hepatocytes were direct, e.g., via EpoR activation, or whether Hif-mediated Hamp1 suppression was dependent on Epo-induced erythropoietic activity (22). To investigate the role of erythropoiesis in the regulation of Hamp1 in this model, Vhlfl/del/Luc;Ubc-cre/ERT2 animals were pretreated with carboplatin (Cp) to achieve efficient BM suppression. Cp-treated and vehicle-treated mice were analyzed 1 day after the final tamoxifen injection (day 8). We found comparable increases in hepatic and renal Epo mRNA levels in both Cp-treated and vehicle-treated Vhl–/– mice, which suggested similar degrees of recombination in

Figure 4
Hif-mediated Hamp1 suppression is Epo dependent. (A). Hepatic Vhl and Hamp1 mRNA levels in control, Vhl/Epo++, and Vhl/Epo+ mice treated with rhEPO (n = 6, 6, and 5, respectively). Right panel shows Hif-1α and Hif-2α protein levels in Vhl/Epo+ livers. Ponceau staining is used to assess for equal protein loading. (B) Epo levels in control, Vhl/Epo++, and Vhl++ livers and kidneys (n = 6, 6, and 3, respectively). Bottom panel shows serum Epo concentrations in control, Vhl/Epo++, and Vhl/Epo+ mice treated with rhEPO (n = 10, 6, and 4, respectively). (C) Hct and reticulocyte counts in control, Vhl/Epo++, and rhEPO-treated Vhl/Epo++ mice and representative FACS analysis plot of CD71/Ter119-stained BM and spleen cells from 1 control and 1 mutant mouse. Percentages of CD71+Ter119+ positive cells are indicated in the right upper quadrant. (D) Liver (n = 8, 4, and 5, respectively) and serum iron concentrations (n = 10, 6, and 4, respectively) in control, Vhl/Epo++, and Vhl/Epo+ mice treated with rhEPO, and H-ferritin protein levels in control and Vhl/Epo+ livers. β-actin served as loading control. Shown are mean values ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, for comparisons of mutants with controls. Vhl/Epo++ (rhEPO), Vhl/Epo double-mutant mice treated with rhEPO.
Hif-associated Hamp1 suppression requires erythropoietic activity. (A) Renal and hepatic Epo (n = 3, 5, and 3, respectively) in control mice and Vhl–/– mutants with or without Cp treatment and liver Hamp1 RNA levels (n = 6, 4, and 3, respectively) in nontreated control, Cp-treated control, and Cp-treated Vhl–/– mutants. Lower panels show Hct, reticulocyte counts, (n = 3 and 4, respectively), serum Epo (n = 3 and 5, respectively), and spleen to body weight ratios in nontreated control and Cp-treated Vhl–/– mice (n = 3 each). (B) Hamp1 mRNA levels in control and Hif2α/Pax3-cre (P3) mutants exposed to chronic hypoxia (10% O2 for 10 days) (n = 3 each) and in thalassemic mice (th3/th3) and control littersmates (+/+) (n = 4 each). Shown are mean values ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, for comparisons with control group or comparison with normoxia. Cp, mice pretreated with Cp; Hx, treatment with 10% O2 for 10 days.

Figure 5

Discussion

To dissect the role of Hif in the regulation of hepcidin in vivo, we have generated a mouse model that permits dissociation of Epo synthesis from Hif activation. From using this model, we provide genetic evidence that Hamp1 suppression requires Epo-induced erythropoiesis and is not directly regulated by either Hif-1 or Hif-2. We furthermore show that the ability of the BM to respond to elevated serum Epo levels with increased rbc production determines whether Hamp1 is suppressed under conditions of chronic hypoxia and/or Hif activation.

Since GDF15 has been proposed to be involved in hepcidin suppression, at least under conditions of ineffective erythropoiesis, such as in patients with thalassemia syndromes (28), we examined serum Gdf15 levels in Vhl–/– and Vhl/Epo–/– mice and in WT mice injected with rhEPO. We found that serum Gdf15 levels were increased in Vhl–/– mice (789 ± 108.5 pg/ml vs. 359.1 ± 40.16 pg/ml) but not in Vhl/Epo double mutants compared with controls. A similar degree of Gdf15 increase was found when WT mice were treated with 3 daily injections of human recombinant EPO at a dose of 200 IU each (Figure 6). EPO treatment was associated with hepcidin suppression (data not shown). Elevated serum Gdf15 levels correlated with increased Gdf15 mRNA expression in total cell isolates from spleen and BM and in Ter119-positive cells purified by immunomagnetic separation (Figure 6 and Supplemental Figure 3A). In contrast with Gdf15, mRNA levels of twisted gastrula-growth factor homolog 1 (Twog1), an erythropoietic cytokine that has been shown to regulate hepcidin in vitro (36), did not change in Vhl mutants compared with littermate controls (Supplemental Figure 3B). Taken together, our data indicate that Gdf15 may participate in the suppression of Hamp1 in Vhl–/– mice.

Discussion

To dissect the role of Hif in the regulation of hepcidin in vivo, we have generated a mouse model that permits dissociation of Epo synthesis from Hif activation. From using this model, we provide genetic evidence that Hamp1 suppression requires Epo-induced erythropoiesis and is not directly regulated by either Hif-1 or Hif-2. We furthermore show that the ability of the BM to respond to elevated serum Epo levels with increased rbc production determines whether Hamp1 is suppressed under conditions of Hif activation in the liver.

The importance of P02 in the regulation of hepcidin has been well established in cell-culture models, in animal experiments, and in humans who were exposed to hypobaric hypoxia (7, 37). Its hypoxic regulation involves the VHL/HIF/PHD oxygen-sens-
ing pathway, as shown in mouse models (8) and in patients with Chuvash polycythemia, a form of familial secondary erythrocytosis that associates with low serum hepcidin levels (5, 6). Chuvash patients are homozygous for specific non–tumor-causing germ line mutations in the VHL tumor suppressor. These mutations impair the ability to efficiently degrade Hif-α under normoxia (5, 38). In line with laboratory findings in Chuvash patients is the Hif-dependent decrease of Hamp1 in Vhl−/− livers. Although Hif acts as an O2-sensitive transcription factor, a direct transcriptional role for Hif was not evident from our studies, which is consistent with recently reported findings in hepatoma cell lines (9). While Hif-1 binding to the Hamp1 promoter has been reported (8), stabilization of Hif-1α alone in Phd2−/− hepatocytes did not result in a transcriptional repression of Hamp1. In this model, Hif-1 activation occurs without the induction of Epo synthesis, which is seen when Hif-2α is stabilized (32). Furthermore, the notion that Hamp1 is not directly regulated by Hif-1 is consistent with genome-wide ChIP analysis in breast cancer cells, which indicates that HIF transcription factors are very unlikely to act as direct transcriptional repressors (39).

Although in cell lines, HIF has been reported to induce matriptase-2 (TMPRSS6) and furin, 2 proteases that modulate HAMP expression by blunting BMP6/HJV signaling (16, 19), hepatic HIF activation without the concomitant increase in Epo transcription does not suppress Hamp1, which would argue against a regulatory role of furin and matriptase 2 in our model. This notion is furthermore supported by a lack of increase in TMPRSS6 and furin mRNA levels in Vhl−/− mice (Supplemental Figure 3D). The ability to synthesize Epo was an absolute requirement for Hamp1 suppression, as indicated by the findings in severely anemic mice (anemia was induced by phlebotomy), which are characterized by low Hamp1 expression (22).

In their report, Pak and colleagues investigated whether anemia itself, elevated serum Epo, or erythropoietic activity was required for Hamp1 suppression. Treatment of anemic mice with Cp, doxorubicin, or a noncytotoxic Epo-blocking Ab inhibited erythropoiesis and raised Hamp1 levels above normemic control levels (22), suggesting that Hamp1 is not directly regulated by either Epo or tissue hypoxia under anemic conditions, but rather by a signal that is associated with increased erythropoietic activity. In keeping with the findings by Pak and colleagues in Cp-, doxorubicin- and anti-Epo Ab–treated mice, Hamp1 levels were also markedly increased in Vhl/Hif1a/Hif2α−/−, Vhl/Epo−/−, and Cp-treated control and Vhl−/− mice, which are characterized by diminished or inhibited erythropoietic activity.

Serum iron has been shown to regulate hepcidin synthesis. Acute depletion of iron results in Hamp1 suppression involving matriptase-2 (41), whereas iron loading increases Hamp1 via TFR2−, HJV−, BMP6−, and HFE-mediated signals (42). In the context of iron-deficiency anemia Hif-1α and Hif-2α are stabilized in Epo-producing tissues, primarily in kidney, but also in the liver, depending on the severity of anemic hypoxia. This results in an increase of serum Epo levels and the suppression of hepcidin (1). Hif-2 is the main

**Figure 6**

Elevation of serum Gdf15 in Vhl−/− mice is Epo dependent. Gdf15 mRNA levels in total spleen and BM cell isolates and corresponding serum Gdf15 levels in pg/ml. (A) Left panels, Vhl−/− mutants and Cre littermate controls (n = 3 and 4, respectively for mRNA analysis; for serum analysis, n = 4 each); middle panels, Vhl/Epo−/− mice and Cre littermate controls (n = 4 each); right panels, WT mice treated with rhEPO or with vehicle (for mRNA analysis, n = 3 and 4, respectively; for serum analysis, n = 6 and 8, respectively). Shown are mean values ± SEM: *P < 0.05; **P < 0.01; ***P < 0.001, for comparisons of mutants with controls. (B) Schematic depiction of Hif’s role in the regulation of hepcidin transcription in hepatocytes. C−, Cre-negative littermate control mice or vehicle-treated WT mice.
Vhl–/– Hif activation in hepatocytes modulates their response to Gdf15, further investigations. While we cannot completely exclude that differences in GDF15 dose responses is not clear and warrants increased cells and in primary hepatocytes, while low-dose GDF15 treatment suppression in human HuH-7 hepatoma HAMP needed to achieve contrast to previous reports where higher doses of GDF15 were concentration of 750 pg/ml (Supplemental Figure 3C). This is in recombinant murine Gdf15 suppressed in Hep3B cells at a HAMP activity and iron utilization. Nevertheless, we cannot exclude that altered intracellular iron levels have contributed to the regulation of Hamp1 in our model. While liver tissue has not been examined, serum iron and ferritin levels are decreased in Chuvash patients and in individuals sojourning at high altitude for 10–12 days (5400 m) (6, 37). However, time-course analysis showed that the decrease of serum hepcidin in subjects ascending to high altitude was rapid and preceded changes in serum ferritin and transferrin saturation. This observation suggests that iron-independent systemic signals must play a major role in the physiologic regulation of hepcidin under hypoxic conditions (44). This notion is supported by clinical observations in patients with β-thalassemia, who have low serum hepcidin levels in the presence of iron overload (45).

Recently, GDF-15 and TWSG1 have been proposed to be erythroid-stress-derived factors, although not erythroid-specific, that mediate hepcidin suppression under conditions of increased erythropoietic activity (24, 36). In particular, high levels of serum GDF15 associate with ineffective erythropoiesis and may reflect a certain type of BM stress or erythroblast apoptosis (28). The role of GDF15 in hepcidin regulation under physiologic conditions and in other pathologic settings, however, is unclear and has been debated. Whereas Tsvg1 mRNA expression levels did not change in BM and spleen from Vhl–/– mice, Gdf15 mRNA levels were elevated and were associated with increased serum concentrations of Gdf15. Although Gdf15 serum levels in Vhl–/– mice were much lower (increased by approximately 2-fold over control) than those reported in β-thalassemia patients (mean of 66,000 pg/ml, ref. 24), our data from Hep3B cells exposed to smaller doses of recombinant Gdf15 support the hypothesis that Gdf15 may have contributed to Hamp1 suppression in Vhl–/– mice. We found that recombinant murine Gdf15 suppressed HAMP in Hep3B cells at a concentration of 750 pg/ml (Supplemental Figure 3C). This is in contrast to previous reports where higher doses of Gdf15 were needed to achieve HAMP suppression in human HuH-7 hepatoma cells and in primary hepatocytes, while low-dose GDF15 treatment increased HAMP in these cells (24). The molecular basis of these differences in GDF15 dose responses is not clear and warrants further investigations. While we cannot completely exclude that Hif activation in hepatocytes modulates their response to Gdf15, elevation of serum Gdf15 in Vhl–/– mice is not likely to result from Hif activation, as a similar degree of increase was found when WT mice were treated with human recombinant Epo, which was also associated with Hamp1 suppression. Studies in humans have not yet demonstrated a significant association between suppression of hepcidin levels and serum GDF15 levels following EPO admin-istration (46), which may relate to the EPO doses used, study size, complexity of regulation, and species-dependent differences in hepcidin regulation. In the context of iron-deficiency anemia, Tanno and colleagues reported that GDF15 serum levels were not elevated (47), while in a report by Lakhal and colleagues, patients with low serum iron had elevated GDF15 levels compared with iron-replete controls (mean of 1048 pg/ml vs. 542 pg/ml) (23). Similarly, increased serum GDF15 levels were found following DFO treatment, suggesting iron-dependent regulation (23). Temporaray increases in serum GDF15 levels were also observed following ascent to high altitude, which associated with increases in serum EPO (44).

In summary, here we have used genetic means to dissect the role of HIF and EPO in the regulation of hepcidin and have shown that Hif-associated suppression of Hamp1 occurs indirectly through Epo-induced erythropoiesis and may involve Gdf15 (Figure 6B). Our data have implications for targeted therapies that aim at exploiting the VHL/HIF/PHD axis for the treatment of anemia and disorders of iron homeostasis.

Methods

Generation of mice and genotyping. The generation and genotyping of Vhl, Epo, Hif1α, and Hif2α (Epa1) conditional alleles as well as Albumin-cre and Ubc-cre/ ERT2 transgenes have been described elsewhere (29, 32, 34). Inducible Cre-mediated global inactivation of Vhl, Hif-1α, Hif-2α, and/or Epo was achieved by generating mice that were homozygous for the Vhl, Hif1α, Hif2α, and/or Epo conditional alleles and expressed a tamoxifen-inducible Cre-recombinase under control of the ubiquitin c promoter Ubc-cre/ ERT2 (29). The following genotypes were generated: (a) VhlHif1αlox/lox;Ubc-cre/ ERT2, (b) VhlHif2αlox/lox;Epa1lox/lox; Ubc-cre/ ERT2, and (c) Vhllox/lox;Epa1lox/lox;Ubc-cre/ ERT2, referred to as Vhl−/−, Vhl/Hif-1–/–, or Vhl/Hif-2–/– after completion of tamoxifen treatment. For the temporary activation of the Ubc-cre/ ERT2 transgenic systemic, mice received 4 i.p. injections of tamoxifen (Sigma-Aldrich) administered every other day at a concentration of 10 mg/ml (~1.5 mg/mouse). Tamoxifen was dissolved in a mixture of 10% (by volume) ethanol and 90% (by volume) sunflower oil. Mice were phenotyped on day 8 after the first tamoxifen injection (outlin of experimental protocol is shown in Supplemental Figure 1). Hepatocyte-specific inactivation of Phd2 (Egr1) was achieved by generating mice that expressed the Albumin-cre transgene and that were homozygous for the Phd2 conditional allele (Egr1lox/lox;Albumen-cre). Cre-negative (Cre−) littermates from the same breeding pair were used as controls in all experiments. The generation and characterization of Hif2α/Pax3–/– mutant mice, referred to as P3 mutants, and thalassic mice (th3/th3 mutants) has been described elsewhere (30, 35).

Stefano Rivella (Weill Medical College of Cornell University, New York, New York, USA) provided liver mRNAs from th3/th3 mutants and littermate controls.

Phenotypic analysis of mutant mice. Hcts were determined by microcapillary tube centrifugation or with a Hemavet 950 analyzer (Drew Scientific). Serum Epo levels were determined by ELISA (R&D Systems); serum and liver iron concentrations were measured using the Iron Assay Kit from BioVision; serum Gdf15 concentrations were measured by ELISA (MyBioSource, LLC). Reticulocyte counts were determined by FACs analysis of whole blood stained with thiazole orange following the manufacturer’s instructions (Sigma-Aldrich). For FACs analysis of BM and spleen-derived erythroid precursor cells, 1 x 10^6 BM or spleen cells were incubated with PE-conjugated anti-transferrin receptor protein 1 (CD71) or FITC-conjugated anti-Ter119 monoclonal antibodies (BD Biosciences — Pharmingen) as previously described (48). For the analysis of Gdf15 mRNA levels, Ter119-positive cells were isolated from BM and spleen by immunomagnetic separation (Ter119-MicroBeads; Miltenyi Biotech). rhEPO (Amenol) was dissolved in 0.1 ml water
and injected i.p. at a dose of 200 IU every day for 3 days prior to mouse phenotyping. For the pharmacologic inhibition of erythropoiesis, mice received a single i.p. injection of Cpg (Sigma-Aldrich), 2.5 mg dissolved in 0.25 ml water 1 day before the first tamoxifen injection. Control animals received 0.25 ml of normal saline. For studies under conditions of chronic hypoxia, mice were exposed to 10% O₂ for 10 days in an animal hypoxia chamber ( Biospherix Ltd) and analyzed immediately after hypoxia treatment.

**DNA, RNA, and protein analysis.** For genotyping, tail DNA was isolated according to Laird et al. (49). Other tissue DNA was isolated using RNeasy Blood and Tissue Kit according to the manufacturer’s instructions (QIAGEN). RNA was isolated using RNeasy Mini Kit according to the manufacturer’s protocol (QIAGEN). For real-time PCR analysis, 1 µl of cDNA was subjected to PCR amplification on an ABI 7300 platform using either SYBR Green PCR Master Mix or Taqman Universal PCR Master Mix (Applied Biosystems). Relative mRNA expression levels were quantified with the relative standard curve method according to the manufacturer’s instructions (Applied Biosystems). 18S ribosomal RNA was used for normalization (50). Primer sequences for the analysis of *Gly* Vhl, Vegf, Dmt1, Tfrc, and Hamp1 have been published elsewhere (30, 32, 35). The following primer sequences were used for mRNA detection: *Epo* (forward, 5′-TGGTCTACGTAGCCTCACTTCA-3′; reverse, 5′-TGAGGCGACATCCACTTCT-3′); *Gdf15* (forward, 5′-CAGAGGCAGGAGACTCGAA-3′; reverse, 5′-GCACCCATAGACCGAGGTGAT-3′); *Twist1* (forward, 5′-AGATGCATTCCCTACACACA-3′; reverse, 5′-AACAAAGCTCTGTCGACGC-3′); *Tmnt* (forward, 5′-ACAGGGTGCCAGTGTACCA-3′; reverse, 5′-GACCATATTAGACCGAGGTGAT-3′); *furin* (forward, 5′-GTGCCTGCTGATCGCCAGC-3′; reverse, 5′-CGCTC- GTCCGGAAAAATTG-3′); and human HAMP (forward, 5′-CACTGTTGCCCATGTTC-3′; reverse, 5′-AGGCCGACAGAAATGTC-3′). Nuclear proteins extracts for Western blot analysis were prepared, and Hist-1t and Hf-2t were detected as previously described (32); H-ferritin and β-actin protein levels were analyzed with antibodies from Alpha Diagnostic International and Sigma-Aldrich.

**Cell culture.** Hep3B cells were cultured in DMEM supplemented with 10% FBS; recombinant Gdf15 (MyBioSource, LLC) was added to the culture medium to achieve a final concentration of 750 pg/ml.

**Statistics.** Data reported represent mean values ± SEM. Statistical analyses were performed with Prism 5.0b software (GraphPad Software) using the unpaired Student’s t test analysis. For consistency, all *P* values reported were derived from unpaired tailed Student’s t test analysis. *P* < 0.05 was considered statistically significant.

**Study approval.** All procedures involving mice were performed in accordance with NIH guidelines for the use and care of live animals and were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Vanderbilt University.

**Acknowledgments**

This work was supported by the Krick-Brooks chair in Nephrology (to V.H. Haase) and by NIH grants R01-DK081646 and R01-DK080821 (both to V.H. Haase). The authors wish to thank Pinelopi Kapitisonu for critical reading of the manuscript.

Received for publication March 27, 2012, and accepted in revised form September 6, 2012.

Address correspondence to: Volker H. Haase, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, C-3119A MCN, 1161 21st Avenue So., Nashville, Tennessee 37232-2372, USA. Phone: 615.343.7254; Fax: 615.322.6854; E-mail: volker.haase@vanderbilt.edu.